Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

Teriparatide

Parathyroid hormone (1-34)

The first 34 amino acids of parathyroid hormone, licensed for osteoporosis.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: Teriparatide

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

1,466
papers on PubMed
979
of them in people
221
randomized trials
172
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Teriparatide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Teriparatide; no amount here is a recommendation.

Teriparatide: on PubMed

What PubMed held for Teriparatide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

1,466
papers
979
in humans
280
clinical trials
221
randomized trials
2012: 76 papers122013: 72 papers2014: 79 papers142015: 92 papers2016: 105 papers162017: 95 papers2018: 85 papers182019: 102 papers2020: 107 papers202021: 92 papers2022: 86 papers222023: 77 papers2024: 87 papers242025: 113 papers2026: 116 papers so far26
Papers per year, 2012 to 2026. The most in one year: 116.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

    Randomized trialLeder BZ, Tsai JN, Uihlein AV, et al. Lancet (London, England), 2015. PMID 26144908

  2. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials

    Meta-analysisLi M, Ge Z, Zhang B, et al. Archives of osteoporosis, 2024. PMID 39312040

  3. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

    Randomized trialTsai JN, Uihlein AV, Lee H, et al. Lancet (London, England), 2013. PMID 23683600

  4. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

    Randomized trialKendler DL, Marin F, Zerbini CAF, et al. Lancet (London, England), 2018. PMID 29129436

  5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation

    ReviewDavis S, Simpson E, Hamilton J, et al. Health technology assessment (Winchester, England), 2020. PMID 32588816

  6. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial

    Randomized trialSim IW, Borromeo GL, Tsao C, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. PMID 32614699

  7. Teriparatide

    StudyVall H, Patel P, Parmar M , 2024. PMID 32644674

  8. Teriparatide

    Review, 2012. PMID 31644031

Search used: ("Teriparatide"[ti]). Run it on PubMed

Research links

Also in Muscle and bone